tirzepatide largo Weight-Loss Health Assessment 2.5mg (25 Units) Per Week Tirzepatide Delivers Again | Climate

A Multi-Receptor Agonist for Advanced Metabolic Research Tirzepatide is a research compound studied for its role in metabolic regulation and energy balance

A 2022 study in the New England Journal of Medicine found that individuals who took a higher dose of the medication lost an average of more than 20% of their body weight over the course of about 16 months

Some people notice small changes within the first few weeks, especially if appetite suppression develops early

Injectable medications compounded with Semaglutide or Tirzepatide

Lancet 398 , 18111824 (2021) H.J.L

Bottom line Mounjaro is a dual-acting GIP/ GLP-1 receptor agonist used for type 2 diabetes and off-label for weight management in people with obesity and overweight